CJC-1295 with DAC 5mg

CJC-1295 with DAC – 2mg Peptide (For Research Use Only)

Overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), developed for non-clinical research into growth hormone (GH) regulation. It is widely studied in laboratory environments for its extended half-life, resulting from the DAC modification, which allows prolonged peptide activity and sustained GH secretagogue effects in animal models and in vitro systems.

Researchers value this compound for its ability to model endocrine responses and investigate GH-IGF-1 axis dynamics under controlled conditions.

⚠️ CJC-1295 with DAC is not approved for human or veterinary use. It is strictly intended for research purposes.

Scientific Background

GHRH is a natural hypothalamic peptide that stimulates the pituitary gland to release GH. However, native GHRH is rapidly degraded in circulation, limiting its utility in experimental studies. CJC-1295 addresses this limitation by incorporating a DAC modification, which binds to albumin and other serum proteins, significantly extending the peptide’s half-life.

This allows researchers to:

• Study long-term GH stimulation without continuous administration

• Model endocrine responses to persistent GH signaling

• Investigate the IGF-1 feedback loop and associated metabolic effects

Mechanism of Action (Research Context)

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, promoting the secretion of endogenous growth hormone. The DAC modification enables albumin binding, which shields the peptide from rapid degradation and renal clearance. This results in sustained bioactivity in research models over several days following a single administration.

Laboratory investigations using CJC-1295 with DAC have observed:

• Increased circulating GH and IGF-1 concentrations

• Prolonged plasma peptide stability (half-life exceeding 7–10 days in some models)

• A consistent pulsatile release pattern mimicking natural GH rhythms

Key Research Areas

CJC-1295 with DAC is commonly used in basic and preclinical research settings exploring:

• Age-related hormonal decline

• GH and IGF-1 dependent signaling pathways

• Muscle tissue physiology and regenerative models

• Body composition, lipolysis, and metabolic regulation

• Synergistic protocols combining GHRH analogs with GHRPs (e.g., GHRP-2, Ipamorelin)

This peptide’s long-acting profile makes it ideal for studies requiring low-frequency dosing protocols and extended endocrine modeling.

Product Features

• Peptide Type: Synthetic GHRH analog

• Modification: DAC (Drug Affinity Complex) for half-life extension

• Research Grade: ≥98% purity (HPLC-verified)

• Storage: Store lyophilized at -20°C; reconstituted at 2–8°C

• Solubility: Sterile bacteriostatic water or acetic acid (as per protocol)

Disclaimer

This product is provided solely for in vitro and animal model research. It is not intended for human ingestion, injection, therapeutic, or diagnostic use. Use must be carried out under institutional biosafety guidelines and by qualified research personnel. CJC-1295 with DAC is not approved by the FDA, EMA, or any medical authority for clinical use.

Certificate of Analysis

CJC 1295 W DAC 5mg – COA – FYP

1. “CJC 1295 with DAC Dosage: A Detailed Guide – Cochrane Handbook”
2. “CJC 1295 DAC vs. No DAC: Understanding the Differences”
3. “CJC 1295 DAC & No DAC: What You Need To Know – Peptide Mania”
4. “CJC-1295 With and Without DAC 2: Complete Guide – sarmguide”
5. “Exploring The Benefits Of Cjc 1295 Dac And How It Can Enhance Research …”